Abstract
Targeted molecular therapies for cancer treatment have shown promise, but also have limitations. In this issue, Heidorn et al. (2010) find that a class of targeted molecular therapies with clinical effectiveness against one melanoma subtype may have adverse clinical effects in another.
Copyright 2010 Elsevier Inc. All rights reserved.
Publication types
-
Comment
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / adverse effects
-
Cell Line, Tumor
-
Humans
-
Melanoma / drug therapy*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-raf / metabolism
-
ras Proteins / metabolism
Substances
-
Antineoplastic Agents
-
Proto-Oncogene Proteins B-raf
-
Proto-Oncogene Proteins c-raf
-
ras Proteins